Payment overview · 2025
General Payments
$3,050.94
94 reported records · 18 companies
Healthcare provider profile · identity verified
Michael L. Fox, D.O.
Allopathic & Osteopathic Physicians|Family Medicine|Addiction Medicine · LIVONIA, MI · NPI 1558444711
Verified facts
What the public records show
CMS Open Payments records show Michael L. Fox, D.O. received $3,050.94 in general payments during 2025 across 94 reported records.
Stryker Corporation accounted for 44.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Trelegy Ellipta, Zubsolv.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Ozempic by this doctor in 2024.
Orexo US, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Zubsolv as an associated drug or biological on 1867 records involving 794 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Zubsolv by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Austedo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Stryker Corporation | Unresolved — no canonical attribution shown | $1,359.02 | 44.5% | 16 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $393.18 | 12.9% | 16 | 2025 |
| Orexo US, Inc. | Unresolved — no canonical attribution shown | $200.86 | 6.6% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $156.04 | 5.1% | 7 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $152.21 | 5.0% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $148.34 | 4.9% | 7 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $132.39 | 4.3% | 7 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $100.23 | 3.3% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $76.13 | 2.5% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $61.13 | 2.0% | 3 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $54.95 | 1.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $54.71 | 1.8% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $39.37 | 1.3% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $34.92 | 1.1% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $32.80 | 1.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.96 | 0.7% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.16 | 0.6% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $16.54 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,753.71 | 80 |
| Travel and Lodging | $1,297.23 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INSPACE Normalized: inspace |
Device | Stryker Corporation | $814.61 | 4 | 2025 |
Source payment records
|
|||||
| ICONIX Normalized: iconix |
Device | Stryker Corporation | $433.05 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $393.18 | 16 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $228.34 | 11 | 2025 |
Source payment records
|
|||||
| Zubsolv Normalized: zubsolv |
Drug | Orexo US, Inc. | $200.86 | 11 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $132.39 | 7 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $100.23 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $88.08 | 4 | 2025 |
Source payment records
|
|||||
| SALVATION Normalized: salvation |
Device | Stryker Corporation | $76.96 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $70.28 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $70.28 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $57.96 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $54.71 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $41.81 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $39.37 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $39.08 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $34.92 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $34.92 | 2 | 2025 |
Source payment records
|
|||||
| ALPHAVENT Normalized: alphavent |
Device | Stryker Corporation | $34.40 | 4 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $32.80 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $27.80 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $27.33 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $21.18 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $20.96 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $20.96 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.32 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $17.16 | 1 | 2025 |
Source payment records
|
|||||
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $16.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Zubsolv zubsolv |
2025 | Zubsolv | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Orexo US, Inc. Exact reporting entity; no affiliate inference |
2025 | Zubsolv open payments reported associated product |
CMS Open Payments — General Payments 1867 supporting records · 794 recipient NPIs · example record 1190507283 |
Zubsolv · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 820 | 178 |
| Gabapentin | Gabapentin | 358 | 87 |
| Trazodone Hcl | Trazodone Hcl | 149 | 53 |
| Duloxetine Hcl | Duloxetine Hcl | 118 | 28 |
| Amlodipine Besylate | Amlodipine Besylate | 114 | 36 |
| Mirtazapine | Mirtazapine | 106 | 33 |
| Tizanidine Hcl | Tizanidine Hcl | 86 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 85 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 84 | 22 |
| Levothyroxine Sodium | Levothyroxine Sodium | 83 | 19 |
| Omeprazole | Omeprazole | 82 | 22 |
| Atorvastatin Calcium | Atorvastatin Calcium | 80 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 77 | 16 |
| Topiramate | Topiramate | 75 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 64 | 11 |
| Losartan Potassium | Losartan Potassium | 64 | 25 |
| Metformin Hcl | Metformin Hcl | 58 | 19 |
| Divalproex Sodium Er | Divalproex Sodium | 54 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 53 | 13 |
| Pregabalin | Pregabalin | 48 | 14 |
| Tamsulosin Hcl | Tamsulosin Hcl | 48 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 46 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 46 | 15 |
| Simvastatin | Simvastatin | 45 | 12 |
| Furosemide | Furosemide | 39 | 13 |
| Meloxicam | Meloxicam | 39 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 39 | 14 |
| Doxepin Hcl | Doxepin Hcl | 38 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 36 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 35 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 33 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Potassium Chloride | Potassium Chloride | 29 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 27 | suppressed |
| Linzess | Linaclotide | 27 | suppressed |
| Ozempic | Semaglutide | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 26 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Zubsolv | Buprenorphine Hcl/Naloxone Hcl | 24 | suppressed |
| Austedo | Deutetrabenazine | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 21 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 20 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 20 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Allopurinol | Allopurinol | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 16 | suppressed |
| Lisinopril | Lisinopril | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Acamprosate Calcium | Acamprosate Calcium | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Azithromycin | Azithromycin | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Jardiance | Empagliflozin | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,050.94 · 94 records | Stryker Corporation | AIRSUPRA, ALPHAVENT, AUSTEDO XR, Auvelity, BREZTRI, CAPLYTA, Cologuard Collection Kit, FARXIGA, ICONIX, INGREZZA, INSPACE, MAVYRET, MOUNJARO, NURTEC ODT, Ozempic, QULIPTA, REXULTI, Rybelsus, SALVATION, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VIVITROL, VRAYLAR, WATCHMAN FLX, ZAVZPRET, ZEPBOUND, Zubsolv | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error